Grünenthal Group: Maren Thurow starts as new Head Global Communications at Grünenthal
20.5.2025 11:53:24 CEST | news aktuell GmbH | Press release
Aachen, Germany, 20th May 2025 - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department since 2021. In her new position, Maren will oversee Grünenthal’s communications operations across all markets and lead the team based at the company’s headquarters in Aachen. She will report directly to CEO Gabriel Baertschi.

This appointment comes at a pivotal moment in Grünenthal’s transformation, following the company’s outstanding financial performance in 2024. Since 2017, Grünenthal’s profitability, measured by adjusted EBITDA, has more than tripled, driven by strategic acquisitions and partnerships such as the acquisition of the US company Valinor Pharma and the product Movantik™ in July 2024. Additionally, Grünenthal continues to advance its key R&D programs, including progressing the Glucocorticoid Receptor Modulator (GRM) and Nociceptin (NOP) Receptor Agonist programs to the next development stages, along with ongoing progress in its Nav compounds. The company is also focusing on accelerating growth in Qutenza™ and its Established Brands, while ensuring a smooth integration of Valinor Pharma and pursuing further strategic acquisitions.
Maren joined Grünenthal in 2021 as Head of Global Commercial Communication and was subsequently the Planning Director for the company’s commercial organization. Prior to joining Grünenthal Maren was a Director at FleishmanHillard, one of the world’s leading global PR firms.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion.
More information: https://www.grunenthal.com
Follow us on: LinkedIn: Grunenthal Group
Instagram: grunenthal
Click here for our Grünenthal Report 2024/2025
For further information, please contact:
Maren Thurow, Head Global Communications at Grünenthal |
Images

Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
fiskaltrust Launches Portugal’s only Certified Fiscalisation Middleware and CashBox10.3.2026 08:30:00 CET | Press release
Integration Partners and Commercial Partners can now access the Portuguese market through fiskaltrust's POS System API, covering full AT (Autoridade Tributária e Aduaneira) compliance.
WELEDA x Stella McCartney: Paris Fashion Week / Skin Food: 100 years of loving skin9.3.2026 13:53:38 CET | Press release
Arlesheim, 09th March 2026 During this season’s Paris Fashion Week, WELEDA is backstage at the Stella McCartney show ensuring radiant skin: make-up artists draw specifically on the trusted nurturing power of the WELEDA Skin Food range to prep and prime the runway models’ skin perfectly for make-up and create a natural glow.
Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm5.3.2026 08:54:06 CET | Press release
Aachen, Germany & Yeoju, South Korea, 5 March 2026 – Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment. In Europe, the product is indicated for the management of peripheral neuropathic pain.
Compax MVNE continues to support Airalo’s eSIM platform2.3.2026 14:46:10 CET | Press release
Compax, a leading solution provider in the MVNO and telco space, will continue to support Airalo, the world’s first and largest eSIM platform.
Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands2.3.2026 10:39:09 CET | Press release
Grünenthal acquired Kyowa Kirin International’s 49% stake in ‘Grünenthal Meds’, a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. Through this acquisition, Grünenthal assumes the sole responsibility of a portfolio comprising 12 brands across six therapeutic areas and >60 markets.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom